1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSmall Business Innovation Research (SBIR) Program is sponsored by NIH National Heart, Lung, and Blood Institute (NHLBI). Funds small businesses developing technologies for heart, lung, blood, and sleep disorders.
Get alerted about grants like this
Save a search for “NIH National Heart, Lung, and Blood Institute (NHLBI)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NHLBI Small Business Program | NHLBI, NIH NHLBI Small Business Program NHLBI Small Business Program The NHLBI is interested in Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) activities that advance the prevention, diagnosis, and treatment of heart, lung, blood, and sleep disorders.
Below is a list of funding opportunity announcements that offer small business entrepreneurs a chance to obtain funding without requirements to give up equity or ownership for early-stage research and development. Get answers to frequently asked questions about the NHLBI Small Business Program .
Learn more about the Innovation and Commercialization Office (I&C) , which coordinates the institute’s Small Business Program, offers services to SBIR/STTR applicants and awardees, provides digital education and online resources, and supports other SBIR/STTR awardee opportunities. Small Business Program Coordinator Julia Berzhanskaya, Ph. D.
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed) SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required) Notice of Special Interest (NOSI): Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) Notice of NHLBI Participation in NOT-AI-24-007 "Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)" Notice of Special Interest (NOSI): Translating Biomaterials-Based Technologies to Commercially Viable Products Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health Notice of Special Interest: Womens Health Research Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44) Innovation and Commercialization Office NHLBI's Small Business Program Frequently Asked Questions Small Business and Academic Innovation Success Stories NIH's Small Business Education and Entrepreneurial Development (SEED) website Innovation and Commercialization Office Inquiry Form
Based on current listing details, eligibility includes: Small businesses in the U. S. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.